Profile: Synta Pharmaceuticals Corp (SNTA.OQ)
14 Mar 2014
Synta Pharmaceuticals Corp., incorporated in March 2000, is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical stage of development. The Company’s drug candidates are discovered and developed internally, using its chemical compound library and integrated discovery engine. During the year ended December 31, 2011, it initiated a Phase 2b/3 clinical trial (GALAXY) of ganetespib in combination with docetaxel in non-small cell lung cancer (NSCLC). In 2011, in addition to focusing on ganetespib program, the Company also focused on its elesclomol and calcium release activated calcium modulator (CRAC) programs.
The Company had two clinical-stage programs and one preclinical-stage program in oncology, as of December 31, 2011. The oncology programs include ganetespib (Hsp90 Inhibitor), elesclomol (Mitochondria-Targeting Agent) and STA-9584 (Vascular Disrupting Agent). Ganetespib is a synthetic, small molecule inhibitor of Hsp90, a chaperone protein that is essential to the function of certain other proteins, for example tyrosine kinases that drive the growth, proliferation, and survival of many different types of cancer. Ganetespib is being evaluated in a range of clinical trials both as a single agent and in combination with other therapies. In 2011, it initiated a randomized, Phase 2b/3 NSCLC clinical trial in combination with docetaxel.
Elesclomol is an investigational drug candidate that triggers programmed cell death (apoptosis), in cancer cells by disrupting cancer cell mitochondrial metabolism. Results from three randomized clinical trials and subsequent research has established that patient baseline serum level of lactate dehydrogenase (LDH), is an important predictor of elesclomol treatment outcome. As of December 31, 2011, elesclomol was in a clinical trial in ovarian cancer in combination with paclitaxel and a clinical trial in acute myeloid leukemia (AML) as a single agent. It is also evaluating the use of elesclomol in combination with paclitaxel in ovarian cancer. STA-9584 is an injectable, small molecule compound that appears to disrupt the blood vessels that supply tumors with oxygen and essential nutrients, and is in preclinical development. In preclinical models, STA-9584 efficiently kills both cancer cells in tumors, as well as the endothelial cells that form blood vessels in tumors.
Inflammatory Disease Programs
The Company has two preclinical-stage programs focusing on treatments for inflammatory diseases. Its Inflammatory Disease Programs include CRACM Ion Channel Inhibitors and IL-12/23 Inhibitors.It has developed small molecule inhibitors of CRACM ion channels expressed on immune cells. The Company’s CRACM ion channel inhibitors have shown anti-inflammatory activity in preclinical studies both in vitro and in vivo, inhibiting T cell and mast cell activity, including cytokine release, degranulation, and immune cell proliferation. The IL-12 cytokine is a switch that triggers the immune response of the T cell, known as T helper type 1 (Th1).
Synta Pharmaceuticals Corp
45 Hartwell Avenue
LEXINGTON MA 02421